source
- FDA grants accelerated approval to Replimune’s melanoma therapy Tudriqev after two prior rejectionsThe Food and Drug Administration has granted accelerated approval to Replimune’s RP1 treatment, which will be marketed under the name Tudriqev, for patients with advanced melanoma. An advisory com…
- FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cutsThe U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…